D
Delinia
Founded to discover and develop novel therapeutics for the treatment of autoimmune and inflammatory diseases
About Delinia
Delinia Bio is a biotechnology company focused on developing and commercializing breakthrough, innovative medicines for patients with serious unmet medical needs. Operating in the healthcare sector, Delinia Bio serves patients suffering from debilitating and chronic diseases, including cancer and autoimmune disorders. The company employs a research-driven approach to discover and develop new therapies that can significantly improve patient outcomes. Delinia Bio's business model revolves around extensive research and development (R&D) activities, followed by clinical trials to ensure the efficacy and safety of their products. Revenue is generated through the commercialization of successful therapies, either by bringing them to market directly or through strategic partnerships and licensing agreements with larger pharmaceutical companies. The company operates globally, impacting the lives of patients in more than 50 countries. Delinia Bio is committed to transparency, strong corporate governance, and ethical practices, ensuring trust among its stakeholders, including patients, healthcare professionals, and partners.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2015
- Headquarters
- San Francisco, United States
- Open positions
- None listed
- Dealroom signal
- 56.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Innovation Management, Developer Tools, Biotechnology, Drug Development, Autoimmune, Patient Care, Immune System, Spinout
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2017 | $300M | $300M | Celgene | — |
| SERIES A✓Equity / VC | Sep 2016 | $35M | $140M | Sofinnova Partners · Atlas Venture | — |
Growth signals
Latest recorded traffic for Delinia is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Other known investors2 additional known investors
Celgene
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Delinia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Delinia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.